The rollout of lenacapavir, a treatment for HIV, is being implemented selectively, raising concerns about who benefits from it and who does not. While lenacapavir was expected to significantly impact the epidemic, the limited geographic distribution highlights issues of access and equity, suggesting that the approach may reflect political decisions rather than a comprehensive strategy to end HIV.

The rollout of lenacapavir (LEN) in Gauteng has faced challenges, with patients in parts of Pretoria being turned away due to delays. It has been two weeks since the initiation of the vaccination program, but access remains limited for some individuals, according to Health-e News.

The rollout of lenacapavir in Gauteng has revealed varying levels of readiness among the 360 designated sites, with 133 located in Gauteng. The first week of the program highlighted these differences in preparedness across clinics, according to Health-e News.

The Ministry of Health reported that the demand for Lenacapavir, an HIV prevention injection introduced in Uganda in April, is surpassing the available supplies. Dr. Herbert Kadama, the ministry’s coordinator for Pre-Exposure Prophylaxis, noted that an increasing number of men are seeking the drug. This announcement was made during a meeting with HIV advocates, researchers, and policymakers.

The Ministry of Health announced that demand for Lenacapavir, a new HIV prevention injection launched in April, is currently exceeding the available supply, particularly among men seeking the twice-yearly treatment. Dr. Herbert Kadama, who coordinates Pre-Exposure Prophylaxis (PrEP) at the Ministry, spoke at a meeting with HIV advocates, researchers, and policymakers about the situation.

Health educators and HIV/AIDS focal persons in the Karamoja sub-region are receiving training on the implementation of Lenacapavir, a new injectable drug for HIV prevention introduced by the Ministry of Health. This training, organized by the Uganda AIDS Commission in Moroto District, aims to equip health communication officers and focal persons with the necessary skills for the rollout of this six-month HIV prevention jab.